What Ломфлокс Treats: Main Uses and Benefits

The medication Ломфлокс (Lomefloxacin) is a medication primarily used in situations involving certain distressing symptoms. Its main indications include managing certain acute bacterial infections of the respiratory and urinary tracts, specifically including acute bacterial exacerbation of chronic bronchitis and various urinary tract infections (UTIs). The medication may be part of symptomatic management, supporting the patient during difficult episodes by easing distress.

---

Symptom Support and Functional Stability

Ломфлокс is commonly used in clinical settings where symptoms become more disruptive during flare-ups and create noticeable physiological strain. Its application is generally in areas of supportive symptom management, applied across conditions presenting with episodic or fluctuating manifestations. The benefit is supportive care, as “it contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.” It is relevant for easing discomfort when symptoms cluster into patterns requiring supportive management.

Quick Fact: Relevant for easing symptoms in conditions involving episodic or fluctuating manifestations.

---

Clinical Scenarios for Use

The medicine assists with maintaining functional stability when symptoms interfere with routine activities. It is applied when supportive symptom management is appropriate, and is commonly used to help with symptoms that escalate temporarily in settings marked by temporary physiological imbalance. It supports the patient during these difficult episodes.

Regulatory References

1. DailyMed Maxaquin (Lomefloxacin) Official Label

Who can and cannot use Ломфлокс? (Lomefloxacin Eligibility)

The population eligibility for using Ломфлокс is strictly defined by government regulatory documents, primarily restricting the medicine based on age, allergy, and pre-existing medical conditions.

---

Official Eligibility and Contraindications

Population Status	Restrictions as per Regulatory Label
Allowed Population	Adult patients (18 years and older) who do not have documented contraindications are the approved group for systemic use.
Absolute Contraindicated	Individuals with known hypersensitivity to lomefloxacin or any other quinolone antibiotic. Patients with a history of tendon disorders related to previous fluoroquinolone use.
Age Restriction	Children and adolescents under 18 years of age are generally non-eligible; use is not established due to potential arthropathic effects.
Physiological/Condition Restriction	Use is not recommended in pregnant women or breastfeeding women. Use is conditional in patients with impaired renal function (e.g., CrCl < 40 mL/min), requiring specific management.

---

Comorbidity and Conditional Use

Ломфлокс is typically contraindicated in patients with a history of myasthenia gravis. Conditional use is required for individuals with CNS disorders that may predispose to seizures, and special caution is advised for older adults due to increased risk factors as documented in the prescribing information.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lomefloxacin (Ломфлокс) based on effects related to absorption, clearance, and additive pharmacodynamic risks. This information is critical for maintaining systemic exposure and managing concurrent use constraints.

---

Key Pharmacokinetic Interaction Constraints

Interacting Product Category	Official Outcome and Restriction
Multivalent Cations (Antacids, Iron, Sucralfate, Didanosine)	Reduced Lomefloxacin Absorption due to chelation. Mandatory timing rule: Lomefloxacin must be administered at least 4 hours before or 2 hours after these agents.
Cimetidine	Increased Lomefloxacin Plasma Concentrations (AUC and Cmax up to 50%) due to decreased renal clearance. This effect may be more pronounced in patients with renal impairment.

---

Pharmacodynamic and Food Interactions

Non-Steroidal Anti-inflammatory Drugs (NSAIDs): Co-administration is associated with an officially documented risk of additive CNS stimulation, including tremors and convulsions.

QTc Prolonging Medicinal Products: Additive pharmacodynamic risk of QTc interval prolongation is documented when Lomefloxacin is co-administered with other medicines known to affect cardiac repolarization (e.g., Class IA and III antiarrhythmics).

Dairy Products (Milk or Yogurt): Administration with these food products is officially noted to result in a statistically significant reduction in systemic exposure (AUC) of Lomefloxacin.

Blocking Bacterial DNA Management Enzymes

Lomefloxacin acts as an inhibitor of two critical bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug specifically binds to and stabilizes the transient DNA-enzyme cleavage complex, blocking the re-ligation step and preventing the repair of the bacterial DNA strand. The molecular interference blocks the pathways required for bacterial replication and gene expression.

---

Causal Chain to Bactericidal Cell Death

The irreversible stabilization of the DNA cleavage complex initiates a mechanistic cascade resulting in the accumulation of double-stranded DNA breaks. The resulting genomic damage induces cellular stress, leading to concentration-dependent bactericidal cell death. This direct killing action against the pathogen population is the key physiological mechanism that results in pathogen elimination.

---

Mechanistic Constraints and Resistance

The function of this mechanism is constrained by two biological factors: mutations in the target enzymes that reduce drug affinity, and the overexpression of bacterial efflux pumps that actively expel the drug. These constraints mechanically lower the concentration of Lomefloxacin at its binding site, which can weaken the bactericidal mechanism by reducing the functional concentration at the target site.

How to Use Ломфлокс (Lomefloxacin) — Administration Guidelines

The usage of Lomefloxacin is structured around its multiple dosage forms, defining distinct administration protocols for systemic and local treatments. The medicine is available in a film-coated tablet for oral use and in specialized ophthalmic and otic solutions for topical application.

---

Standard Dosing and Administration

Feature	Instruction
Oral Dose and Frequency	400 mg once daily (q.d.) for approved systemic infections.
Topical Dosing	Typically 1 to 2 drops instilled into the affected eye(s), following a schedule that often reduces frequency after the initial days.
Intake Condition	Oral tablets may be administered without regard to meals (with or without food) but should be taken with ample fluid, such as a full glass of water.
Course Duration	Oral treatment generally lasts 10 to 14 days, depending on the indication. Topical treatment courses are typically shorter, such as 7 days.

---

Procedural and Population Constraints

General guidelines include specific constraints tied to the proper use of Lomefloxacin. For patients with severely impaired kidney function (creatinine clearance le 10 mL/min/1.73 m^2), a dose modification is required. Conversely, no specific adjustment is necessary solely for older adults, provided their renal function is stable. The topical solutions are for external use only and are strictly prohibited from being injected or swallowed. For ophthalmic application, patients are instructed to remove contact lenses prior to use.

Research Evidence / Overview of Studies for Ломфлокс

---

Evidence for Use in Acute Exacerbations of Chronic Bronchitis

Research has explored the use of Lomefloxacin for treating acute bacterial exacerbations of chronic bronchitis (ABECB). The available evidence includes short-term Randomized Controlled Trials (RCTs) and comparative multicenter studies, which focused on adult patients whose exacerbations were linked to susceptible bacterial infections.

Studies monitored outcomes related to physical discomfort (such as changes in acute respiratory symptoms) and outcomes related to the microbiologic status (assessment of bacterial presence). Findings describe patterns observed during the defined time intervals. The research reports changes measured during the short treatment course and the immediate post-treatment follow-up.

What remains uncertain is the long-term impact of Lomefloxacin. Follow-up durations were limited, typically monitoring patients for a short period after therapy completion. Therefore, there is limited information for long-term outcomes regarding the frequency of future exacerbations or sustained stability.

---

Evidence for Use in Urinary Tract Infections

Lomefloxacin was studied for use in various urinary tract infections (UTIs), particularly those characterized by acute changes. The evidence for this use is structured around RCTs and Systematic Reviews/Meta-analyses. These studies primarily focused on adult patients with symptoms of acute, uncomplicated UTIs.

Researchers examined microbiologic assessment endpoints (assessment of the bacterial pathogen in the urine) and clinical evaluation endpoints (symptom changes, such as urinary frequency or pain). Research reports changes measured during the study period, contributing to understanding the microbiologic status.

However, the existing evidence focuses heavily on uncomplicated infections. Data for certain groups remain insufficient, particularly those with complicated or recurrent UTIs. Furthermore, broader regulatory shifts affecting the entire fluoroquinolone class have created a limited scope for the general applicability of this evidence, especially when considering alternative treatments for simple infections.

Key Studies & References

1. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults (RCT for UTI, comparative evidence)
2. A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections (Comparative trial for complicated UTIs, post-marketing follow-up)
3. Urinary Tract Infections - Experience with Lomefloxacin (Study on complicated UTI population, special populations data)

Common questions about Ломфлокс (FAQ)

Q: How should I store this medication?

Official labeling, such as that provided by the FDA, states that you should store the tablets at controlled room temperature. This specific temperature range is generally between 20^circmathrmC to 25^circmathrmC (68^circmathrmF to 77^circmathrmF). The regulatory documents specify these conditions to maintain the product's quality.

---

Q: Can I drink alcohol while taking this medicine?

The official product information advises caution when using this medicine if you consume substantial quantities of alcohol or have a history of liver disease. This is due to the potential for both the drug and alcohol to affect the liver function. Questions about using this medication with alcohol should be directed to a healthcare professional.

---

Q: Is it safe for long-term use?

Official label information describes the use of this medication over the long term for reducing cardiovascular events. While generally well-tolerated, the documentation notes that rare side effects, such as reversible cognitive impairment and increases in blood sugar levels, have been observed. Patients receiving long-term treatment may require periodic monitoring for certain side effects, as outlined in the official documentation.

Official Storage and Handling

Lomefloxacin (Maxaquin) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The regulatory documentation permits brief temperature excursions between 15 C and 30 C. The medicine should be kept in a tight container and protected from light to maintain the stability of the active ingredient. As a mandatory safety requirement, the product must be stored out of the reach of children.

Storage Classification	Regulatory Defined Condition
Temperature	Controlled Room Temperature (20 C–25 C)
Protection	Store in a Tight Container; Protect from Light
Child Safety	Keep out of Reach of Children

Official Disposal Instructions

Unused or expired Lomefloxacin must be disposed of according to official guidelines. Patients are advised not to flush the tablets down the toilet or pour them down a drain. The recommended disposal method is to use a community drug take-back program. If a take-back program is unavailable, the medicine can be mixed with an undesirable substance and placed in a sealed bag before disposal in household trash.